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Summary The sensitivity to melphalan of clones derived from individual lung colonies produced by i.v.
injection of cells of the MT murine mammary carcinoma (caMT) and its melphalan-resistant sub-line
(MTME16) has been examined. A degree of clonal heterogeneity was observed which was greater than could
be explained by experimental variation. The distribution of melphalan sensitivities in both wild-type caMT
and MTME 16 raises questions as to the validity of a two-compartment model of drug-resistance development
in tumours. A more complex model, possibly involving a continuous spectrum ofdrug sensitivity, is required.
Differences in the sensitivity of the clonal lines of wild-type caMT in various passages were observed and
this would appear to be due to phenotypic instability in these lines. This suggests that to use survival data
from clones which have been passaged many times for predicting the response of the parent tumour may be
misleading.
Many tumours have been shown to be hetero-
geneous with respect to drug sensitivity. Highly
drug-resistant cells have been isolated following
drug treatment (Clements, 1975) and differences in
sensitivity of untreated sub-lines, clonal or non-
clonal, have been demonstrated (Heppner et al.,
1978; Stephens & Peacock, 1982; Brouwer et al.,
1983).
The presence of cells with a reduced drug
sensitivity results in a diminished ability to cure
tumours and selection of these cells by chemo-
therapy leads to the development of a drug-
resistant tumour. Existing models which describe
these phenomena have been based on a situation in
which a tumour may be composed of two discrete
populations, one drug-sensitive and the other highly
resistant (Skipper et al., 1978; Goldie & Coldman,
1979). We have previously described the develop-
ment of resistance to cyclophosphamide, cis-
platinum and melphalan in the MT murine
mammary carcinoma (McMillan et al., 1985). In
each case it appeared that the nature of this
resistance development was inconsistent with
existing models of resistance development based on
the selection of a totally resistant sub-population of
tumour cells.
Rarely have more than three or four sub-lines
from any tumour been examined for their drug-
sensitivity so little idea can be gained from
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published data about the validity of a two-
compartment structure of drug-sensitivities in
tumour cell populations. In addition the drug-
sensitivity of sub-lines has often been examined
when they have been maintained for several
passages following their isolation from the original
tumour. Consequently it is not known how
accurately these sub-lines reflect the distribution of
cellular sensitivity in the original tumour. While it
was appreciated that to fully characterize the clonal
variation in a tumour is probably impossible, due
to the extensive intratumour heterogeneity, it was
the aim of this study to examine the melphalan-
sensitivity of a number of clones of the MT
carcinoma in an attempt to gain an insight into the
nature of the variation in this tumour. The clonal
variation in the sensitivity to melphalan in the MT
carcinoma was therefore examined to investigate
the validity of a two-compartment structure in this
tumour.
Materials and methods
Tumours and mice
The MT carcinoma (caMT) was carried routinely
by i.m. transplant of a tumour brei into the
gastrocnemius muscles of 8-10 week old male
WHT mice which were obtained from the Institute
of Cancer Research breeding centre. -MTME16 is a
melphalan-resistant sub-line which was derived by
multiple treatments of caMT with melphalan
(McMillan et al., 1985). This line had a three fold
increase in the D0o of the in vitro melphalan dose-
survival curve (1.9pgml -1 compared with
0.63Mgml1 for wild-type caMT).
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Derivation ofclonal lines
Sub lines of caMT and MTME 16 were derived
from lung colonies. There is some evidence to
suggest that lung colonies are clonal in origin
(Poste, 1982) and this method of cloning has
been used previously (Stephens & Peacock, 1982).
The lines isolated from these two tumours will
therefore be referred to as 'clones'. A single cell
suspension of the tumours was injected together
with heavily irradiated cells (106 per mouse), and
plastic microspheres (106 per mouse) into the tail-
vein of unanaesthetised mice. Mean lung cloning
efficiencies of 3.5 x 10-3 and 1.3 x 10-4 were
obtained with caMT and MTME16 respectively
and sufficient viable cells were injected to give 1-5
lung colonies per mouse. Lung colonies were 2-
3mm diameter 10-12 days after injection and at
this stage the lungs were removed. Eleven colonies
were isolated from each line and single cell
suspensions were prepared from each individual
lung colony. The cells of each clone were tested for
their in vitro melphalan sensitivity (passage 1) and
for every clone derived from wild-type caMT, 105
cells were also implanted i.m. into mice. When the
resulting tumours had reached a size of 0.2 to 0.5 g
further in vitro assays were performed. This was
designated passage 2. Further sets of assays were
performed in subsequent passages.
Preparation of tumour cell suspensions
Tumour disaggregation was performed as pre-
viously described (Stephens et al., 1978). Briefly,
tumour tissue was chopped finely with crossed
scalpels and incubated for 30min at 37°C in PBS
containing trypsin (0.2%, Bacto-Trypsin, Difco
Laboratories) and Deoxyribonuclease I (DNase,
0.05 mgml -1, Sigma Chemical Company), with
continuous agitation. After incubation the suspen-
sion was given 10 vigorous shakes to dislodge
loosely attached cells from the remaining tissue
fragments and a further 0.05mgml-1 DNase was
added. The suspension was filtered through
polyester mesh with 35 m pore size, the cells were
washed once in culture medium (Ham's F12 with
17% Donor calf serum and antibiotics) and were
finally suspended in culture medium.
The suspension was counted under phase
contrast using a haemocytometer. All refractile cells
were counted taking care not to include normal
cells which were obviously much smaller than the
tumour cells.
In vitro drug treatment and tumour cell survival
assay
For in vitro cytotoxic drug treatment a cell
suspension at a concentration of 5 x l04 cells per ml
was divided into 2ml aliquots. These were gassed
with 90% nitrogen, 5% CO2, 5% oxygen at 37°C
for 1.5 to 2.5h. This period was necessary, to bring
the suspensions to the correct temperature and to
bring the culture medium to physiological pH.
Melphalan ('Alkeran', The Wellcome Foundation
Ltd), which had been dissolved at 10mgml-1 in
acid ethanol (20mll-1 IN HCL in absolute ethyl
alcohol) and then diluted in culture medium, was
added to the cell suspensions. Up to 5 doses of
drug plus a control were used to determine the
survival curve of suspensions obtained direct from
lung colonies (Passage 1) and 7 doses were used for
other passages.
The cells were incubated with the drug for 50min
at 37°C, whilst undergoing continuous gentle
agitation. They were then centrifuged at 1500r.p.m.
for 10min, the supernatant removed and the cells
resuspended in culture medium.
A slight modification of the soft-agar assay
described by Courtenay (1976) was performed to
assess clonogenic cell survival. A maximum of
20,000 of the cells to be assayed were mixed with
10,000 heavily irradiated cells in 0.3% agar and
were added to solidified base layers of 0.5% agar in
each of three 30mm plastic tissue culture petri
dishes. The upper layer was allowed to solidify for
15 minutes at room temperature after which the
dishes were placed in an incubator at 37°C and
maintained in a water saturated atmosphere of 90%
nitrogen, 5% oxygen and 5% CO2.
Twelve to 14 days after preparation of the
cultures colonies were counted, taking care to
distinguish between 'compact' tumour cell colonies
and 'diffuse' host cell colonies (Stephens et al.,
1978). Survival was expressed as a surviving
fraction (SF) where:
SF=plating efficiency treated cells
plating efficiency control cells'
The data for each assay were fitted by a least
squares regression analysis and the slopes of the
survival curves are given as D1o values (the dose
required to reduce survival by one decade).
Results
Wild-type MT carcinoma
The survival curves for the eleven clones of wild-
type caMT in passages 1,2 and 4 are given in
Figure 1. A wide range of melphalan-sensitivities
was evident at each passage with variation being
seen in both the slope and the extrapolationINTRATUMOUR VARIATION IN DRUG SENSITIVITY
Passage 2 Passage 4
0 0.5 1.0 1.5 2.0 0 0.5 1.0 1.5 2.0 0 0.5 1.0 1.5 2.0
Melphalan dose (,ug ml-')
Figure 1 Melphalan dose-survival curves for clones of caMT in passages 1, 2 and 4 after their isolation from
the parent tumour. All curves are from least-squares regression analysis of the data points (Correlation
coefficients all >0.95).
numbers of the curves. The distribution of D10
values at each passage shows this variation in slope
(Figure 2) and it is also suggests that there was a
general trend for the clones to become more
resistant to melphalan after the first passage.
This decrease in sensitivity was confirmed by the
mean D1o values which were (with s.d.) 0.62+0.17,
0.85+0.1 and 0.87+0.16 pgml-l for passages 1, 2
and 4 respectively. The distributions of D1o values
Wild-type caMT
Passage 1
for passages 1 and 2 were significantly different
from each other (P<0.01, Mann-Whitney U-test)
as were the distributions of 1 and 4 (P<0.01) but
passages 2 and 4 were not. Figure 3 shows that this
trend did not hold true for each individual clone
since in two instances the D0o value was lower in
passage 2 compared with passage 1.
The range of D1o values in passage 1 was slightly
greater than in the other passages and all three
were more variable than was seen when 10 i.m.
tumours from the same clone were tested with 3 drug
doses plus one control per tumour (Figures 4 and
5). For this the mean and standard deviation of the
D10 values were 0.78+0.09yigml-1. The difference
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Figure 2 The distribution ofD1o values of the in vitro
melphalan dose survival curves for clones of caMT
tested at passages 1, 2 and 4. Mean D1o values (with
standard deviations) were 0.62+0.17, 0.85+0.10 and
0.87+0.16jig/ml for passages 1, 2 and 4 respectively.
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Figure 3 The slopes of the in vitro melphalan dose-
survival curves (given as D1o values) for eleven clones
of caMT tested at different passages. Each line
connects the D1o values for an individual clone.
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Figure 4 Melphalan dose-survival curves produced by
10 independent assays on a single clone of caMT. All
curves are from least-squares regression analysis of the
data points (correlation coefficients all >0.98).
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Table I Parameters of survival curves
derived from data from all passages
(except passage 1) for clones ofcaMT
Clone D +n
4 0.71 2.2
5 0.67 1.3
6 0.61 1.7
7 0.65 2.1
11 0.95 1.6
12 0.82 2.3
13 0.85 2.3
14 0.90 1.7
15 0.88 1.3
16 1.04 1.4
17 0.83 1.4
Mean=0.81.
s.d. =0.13.
+n=extrapolation number.
MTME16
The distribution of D1o values for the dose-survival
curves for clones of MTME16 in passage 1 is given
in Figure 6. The variation in these values is much
greater than was seen for any passage of caMT
clones, the range being from 0.49 to 2.01 pgml-1.
As would be expected from the resistant nature of
MTME16 the average D1o (0.94+0.44ygml-1) was
greater than that for clones of caMT.
1.0
Figure 5 The distribution of D,o values for 10
independent in vitro melphalan sensitivity assays on a
single clone ofcaMT (mean 0.78+0.09 ig/ml).
between the variance in passage 1 and the 10 tests
on a single clone was significant (P<0.05) when
analysed using an F-test for homogeneity of
variances. The differences between passages 2 or 4
and the tests on one clone were not significant. The
correlation coefficients for the lines fitted to the
data were >0.95 in all cases which suggests that
very little of the variation seen was due to the
scatter of data points around the fitted lines.
In many studies the clonal heterogeneity of a
tumour has been inferred from the sensitivity ofsub-
lines which had undergone many passages after the
isolation (e.g. Calabresi et al., 1979). Following this
approach data derived from passages 2-5 have been
combined for each clone and the parameters of
these curves are given in Table I. The mean Dio
value for these curves 0.81+0.13pgmlP1 and the
range is from 0.61 to 1.04ugml-'.
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Figure 6 D,o values of in vitro melphalan dose-
survival curves for clones of MTME16 (mean
0.94+0.44pgm 1)
Discussion
Studies of intratumour heterogeneity with respect to
drug sensitivity have largely been performed on
sub-lines which have been maintained for many
passages following their isolation from the parent
tumour. In this study we have measured the
melphalan-sensitivity of several clones of the MT
carcinoma when they were at a very small size in an
attempt to minimize the diversity which may have
. . . . . . . . L I
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arisen during the growth of the clones. Extensive
diversity, beyond that caused by experimental
variation, was still seen in the melphalan-sensitivity
of the clones, thus suggesting that the wild-type MT
carcinoma is indeed heterogeneous in its chemo-
therapeutic response.
As well as interclonal variation it also appeared
that the cells obtained directly from lung colonies
were generally more sensitive than the cells of the
intramuscular tumours in later passages. There are
two possible explanations of this. Firstly, variation
in the vascularization of tumour masses of different
sizes could lead to differences in their proliferative
state (Gunduz, 1981) and this in turn could affect
their drug sensitivity. However, the assays reported
here were performed in vitro and drug treatment
was given after up to 2.5h of incubation at 370C,
which may have reduced any differences induced by
the environment within the parent tumours.
The other possibility is that differences between
passage 1 and subsequent passages could reflect
changing properties of the clonal lines. Instability
of isolated clonal lines has been seen with respect to
metastatic potential (Poste et al., 1981), therapeutic
sensitivity (Welch et al., 1984b), karyotype
(McMillan, unpublished results) and various other
cellular characteristics (Welch et al., 1984a). This
shift in cellular characteristics associated with
passage in vitro or in vivo has been termed
'phenotypic drift' (Neri & Nicolson, 1981). It is
possible that in passage 1 the clones had not yet
reached an equilibrium state, and during growth
from passage 1 to 2 changes in the tumour cell
population may have taken place. Since every clone
did not show the same general trend in the drift to
resistance (Figure 3) this phenotypic instability
seems to be the most likely cause of the inter-
passage variation. It is not known whether selection
pressures which are specific to the i.m. site act on
the variants produced by this instability to produce
these inter-passage changes.
An important question posed by these data is,
which of the passages most closely reflects the
inherent characteristics of the clones if they had
been left in the parent tumour? If, as has been
previously suggested, diversification does take place
in clonal lines then one must conclude that passage
1 must reflect most accurately the properties of the
cells which originally formed the lung colonies.
Even then, however, the number of cells required
for the sort of assay used here precludes an
assessment of drug sensitivity before any
diversification may have taken place.
It is noticeable that the average D1o of
0.62igmlm1 in passage 1 is closer than the other
passages to the DIo of the parent tumour
(0.63 gml-1). This may further support the
suggestion that passage 1 is most representative of
the sensitivity of the cells in the parent tumour.
However, due to the extent of the variation in
tumours a correlation between the average
sensitivity of a small number of clones and that of
the parent tumour might have occurred by chance.
Overall these data leave some doubt as to the
significance of reports of tumour cell heterogeneity
in which isolated sub-lines had been passaged many
times before their drug-sensitivity was tested. In
addition, if the phenotypic drift seen here occurs in
metastases, the formation of which may be
considered to be a natural cloning process in some
cases, this could have serious consequences for the
treatment of disseminated disease. Not only will
metastases vary in their therapeutic sensitivity due
to the heterogeneity of the parent tumour, but the
rapid evolution of the cells within each metastasis
will add greatly to this diversity. Thus, it may be
impossible to produce a single treatment regime to
eliminate all of the tumour cells within a given
patient.
Examination of the sensitivity of MTME16
revealed that only one of the eleven clones
examined showed a sensitivity which was near the
D10 of 1.9pgml-I seen for the parent MTME16. It
is not clear whether the presence of sensitive cells in
MTME16 is due to the failure to eliminate all
sensitive cells during the development of the
melphalan resistant line. Since the clones were
isolated from the fifteenth passage after the
cessation of melphalan treatment it is possible that
these cells are the result of the reversion of the
resistance phenotype in some cells. Even though
melphalan-resistance was very stable in this line
when growth delay was measured (McMillan et al.,
1985) a significant increase in the proportion of the
sensitive cells may have occurred without detection
by the growth delay assay.
A reduced lung cloning efficiency for resistant
cells could also explain the low proportion of
resistant clones. The lower lung cloning efficiency
of MTME16 compared with wild-type caMT
(1.3 x 10-4 and 3.5 x 10-3 respectively) seems to
support this possibility. If this is the case then it
demonstrates once again the dangers of trying to
infer the sensitivity of the parent tumour from that
of isolated clones.
A further question raised by these data is
whether the extent of the diversity seen in caMT
clones is sufficient to explain the development of
drug resistance previously described in this tumour
(McMillan et al., 1985) by a purely selective
process. No caMT clones were isolated which had a
sensitivity similar to the melphalan resistant line of
caMT (MTME16) however, only a small number of
clones were examined and highly resistant clones758 T.J. McMILLAN et al.
may be rare. What these data do suggest is that a
simple two-compartment model in which cells are
either sensitive or highly resistant may not be valid.
The distribution of drug sensitivity seen here
implies that a continuous spectrum of sensitivity
may be a more accurate model (Stephens et al.,
1985). An alternative, however, which cannot be
proved or disproved by the current data, is that the
distribution of sensitivities may have two peaks,
one with a low mean DI0, and the other with a
high D10, with separate distributions around each
mean.
The presence of clones of intermediate sensitivity
was seen in MTME16, for example one clone had a
D1o of 1.31Mgml-1, compared with 0.63 and
1.9pgml-P for wild-type caMT and MTME16
respectively. This again suggests that a simple two
compartment model may not be adequate since the
presence of clones with intermediate sensitivity has
no place in this model. It is not clear whether
clones of intermediate sensitivity pre-exist in the
parent tumour, are induced by drug treatment or
are the result of the gradual loss of resistance of
more highly resistant cells. However, whichever of
these is true, these clones may influence the overall
therapeutic response of the tumour.
Obviously the exact distribution of sensitivities in
a tumour cannot be determined without examining
a very large number of clones. Thus the influence
of a spectrum of sensitivities model on the initial
therapeutic response and the subsequent develop-
ment of resistance cannot be determined. However,
some broad predictions can be made using this
concept. Firstly, a range of sensitivities would result
in a dose-response curve which was not a true
exponential. Since most published drug dose-
response curves are exponential this would appear
to invalidate such a model. However, in most cases
the scatter of data in clonogenic survival assays is
such that a degree of curvature of the curve may
not be detected.
Secondly one would expect the development of
drug-resistance during repeated treatment to be
slowed down, compared with a model involving the
selection of a single highly drug-resistant sub-
population. This is due to the survival of cells of
intermediate sensitivity if they are present in the
tumour in sufficient numbers to avoid being totally
eliminated by whatever dose of drug is used. A
slow rate of resistance development was found
when caMT was treated with melphalan, cyclophos-
phamide or cis-platinum (McMillan et al., 1985).
The presence of a spectrum of drug-sensitivities
could therefore have important implications for
cancer chemotherapy. Validation of such a model
will require much more extensive investigations of
the clonal composition of tumours, studies which
may be complicated significantly by the apparent
clonal instability observed here.
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